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of upper and lower airway inflammation
in atopic children
Mirella Profita, PhD,a Stefania La Grutta, MD,b Elisiana Carpagnano, MD,c Loredana
Riccobono, PhD,a Rossana Di Giorgi, PhD,a Anna Bonanno, PhD,a Elisabetta Pace, MD,a
Giovanni Bonsignore, MD,a Jean Bousquet, MD,d Antonio Maurizio Vignola, MD,
PhD,a* and Mark Gjomarkaj, MDa Palermo and Bari, Italy, and Montpellier, FranceBackground: Exhaled nitric oxide (FENO) and exhaled breath
condensate (EBC) are noninvasive methods to assess
inflammation.
Objective: To investigate the role of the FENO and of the EBC
pH and IL-5 levels in atopic children.
Methods: We evaluated oral and nasal FENO and the pH and
IL-5 of oral and nasal EBC in children with atopic dermatitis
(AD; n 5 18), allergic rhinitis (AR; n 5 18), intermittent
asthma (n 5 21), moderate persistent asthma (n 5 18), and
healthy controls (HCs; n 5 16).
Results: Oral FENO was significantly increased in asthma,
whereas the nasal values were increased in AR and asthma
in comparison with HCs. The pH of oral EBC was lower in
AD and asthma than in AR and HCs, whereas the nasal
levels were lower in AD, AR, and asthma than in HCs.
The oral IL-5 was higher in AD, AR, and asthma in
comparison with HCs, whereas the nasal IL-5 concentrations
were higher in asthma and AR than in HCs. In AR, the nasal
FENO correlated with the IL-5 values and with the disease
duration. In intermittent asthma, oral and nasal pH inversely
correlated with the exacerbations, whereas in moderate
asthma, the nasal IL-5 positively correlated with exacerbations.
In AD, the oral and nasal IL-5 positively correlated with the
serum IgE.
Conclusion: These markers of nasal and bronchial
inflammation, accessible with noninvasive techniques,
might be useful to identify patients with uncontrolled
diseases and to verify the usefulness of new therapeutic
approaches.
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Atopic dermatitis (AD), allergic rhinitis (AR), and
asthma have been recently defined as systemic allergic
disorders with variable end-organ manifestations.1,2 AD
and AR often coexist with or precede the development
of asthma. These atopic diseases share several pathophys-
iologic features, including inflammatory mediators and
allergic triggers.3,4
The upper and lower airways classically are the targets
of inflammatory processes in AR and asthma, respec-
tively.3,4 Despite this evidence, inflammatory processes of
the lower respiratory tract can be observed in subjects
without asthma with AR, and upper airway inflammation
may be present in subjects with clinical signs of asthma.3,5
Furthermore, patients with severe AD and mild asthma
have more pronounced late asthmatic responses than
patients with asthma without AD.6 This evidence, taken
together, strongly supports the concept of a united airway
disease in atopic patients.2
Exhaled breath condensate (EBC) and exhaled nitric
oxide (FENO) methods have been recently described as
possible tools to assess the inflammatory status in the
upper and lower airways and to evaluate the clinical
assessment of related diseases7 despite some unresolved
questions about their applications.8 In particular, the
measurement of the oral EBC inversely correlates with
other indices of lower airway inflammation, and it
decreases during acute exacerbations in asthma.9,10
FENO levels are increased in children with asthma, corre-
late with the number of exacerbations, and are related to
the acidification in the airways of subjects with
asthma.10,11 Only a few studies have addressed the com-
parative use of oral and nasal EBC and FENO in asthma,
AD, and AR.
This work was performed to evaluate the use of
noninvasive techniques including the evaluation of oral
and nasal FENO and of the pH and IL-5 levels in the oral
and in the nasal EBC for the detection of upper and lower
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nAbbreviations used
AD: Atopic dermatitis
AR: Allergic rhinitis
EBC: Exhaled breath condensate
FENO: Exhaled nitric oxide
HC: Healthy control
ICS: Inhaled corticosteroid
airways inflammation in atopic children with AD, peren-
nial AR, and allergic asthma.
METHODS
Subjects
We studied 18 children with AD, 18 with AR, and 39with asthma,
and 16 age-matched healthy controls (HCs) with no acute respiratory
symptoms in the last 4 weeks.
Atopic dermatitis diagnosis was performed at the study entry
according to diagnostic criteria of Hanifin and Rajka.12 AD severity
was measured through the SCORAD index.1 Three children had
severe, 8 moderate, and 7 mild AD.
Allergic rhinitis diagnosis was performed at the study entry
according to Allergic Rhinitis and its Impact on Asthma guidelines.13
Six children had intermittent mild, 4 had intermittent moderate severe,
4 had persistent mild, and 4 had persistent moderate severe rhinitis.
PatientswithADandARwere enrolled after completing antihistamines
or systemic or topical steroid treatment.14 Children with AD and AR
concluded the treatment 3 weeks before entering the study.
Asthma diagnosis and assessment of severity were performed
according to Global Initiative for Asthma guidelines.15 Twenty-one
children had intermittent asthma (treated with short-acting b2-ago-
nists on demand during the last 6 months), and 18 children had mod-
erate asthma (treated with fluticasone proprionate 250 mg inhaler
device Diskus 1 a day; GlaxoSmithKline, London, United Kingdom).
During the selection of the patients, 5 patients with unstable
rhinitis and 9 patients with unstable asthma were excluded from the
study. Unstable disease was defined on the basis of the persistence of
nasal or bronchial symptoms with frequent use of rescue medications.
Asthma exacerbation was defined as increasing symptoms and signs of
asthma (coughing, wheezing, shortness of breath) unresponsive to the
patient’s routine asthmamedication and requiring an unscheduled visit.
No patients had nasal polyposis or bronchial or respiratory tract
infections or had a severe exacerbation of asthma resulting in
hospitalization during the last month. Within 1 day from the breath
condensate collection, all subjects performed pulmonary function
tests as recommended by theAmerican Thoracic Society.16 The study
was approved by the local Ethics Committee, andwritten consent was
obtained from parents.
Assessment of atopic status
All subjects were investigated for their clinical history and
underwent a careful diagnostic evaluation including skin prick test
and total serum IgE measurements. Skin prick test was performed as
previously described.17House dust mite (Dermatophagoides pteronys-
sinus and Dermotophagoides farinae) monosensitized patients were
included in the study to select a population as homogeneous as possible
and to avoid a bias caused by the seasonal exposure. Serum samples
were collected, and total serum IgE and specific IgE levels were deter-
mined by CAP System (Pharmacia-Upjohn, Uppsala, Sweden).Nitric oxide measurement
Oral and nasal FENO were determined by chemiluminescence
(NiOX, Aerocrine, Sweden) following American Thoracic Society
recommendations.18
To evaluate the nasal FENO, the nasal samples were obtained from
1 nostril. The patients were instructed to blow up the cheeks to elevate
the mouth pressure to isolate the nasal cavity from the rest of the res-
piratory system.19 Before the measurements of oral and nasal FENO,
the subjects rinsed out their mouths. The units of FENOmeasurements
were parts per billion.
EBC collection
The oral EBC was collected using a condenser that allowed the
noninvasive collection of the nongaseous components of the expired
air (EcoScreen; Jaeger, Wurzburg, Germany). Children were asked
to breathe at a normal frequency and tidal volume, wearing a nose
clip, for a period of 15 minutes. A temperature of 2108C inside the
condensing chamber throughout the collection time produced imme-
diate sample freezing. Samples were stored at 2708C until analysis.
The nasal EBCwas collected according toGriese et al,7 withminor
modifications. After applying a nasal mask to the EcoScreen, children
were asked to breathe through their noses, with their mouths closed.
Before the collection, the subjects rinsed out their mouths. The oral
and nasal condensate, at least 1mL,were stored at2808Cuntil analysis.
EBC measurement of pH
A stable pH was achieved in all cases after deaeration/decarbon-
ation of breath condensate specimens by bubblingwith argon (350mL/
min) for 10 minutes. pH was then measured within 5 minutes of
condensate collection by means of a pH meter (Corning 240; Science
Products Division, New York, NY) with a 0 to 14.00 pH range.
EBC measurement of IL-5
Determination of the absolute values of IL-5 in EBC was assessed
using commercially available specific ELISAs (Amersham Biosci-
ences, UK Limited, Little Chalfont Buckinghamshire, UK). Limits of
detection were less than 2 pg/mL.
Reproducibility
Two successive measurements of oral and nasal FENO, pH, and
IL-5 in EBC of the subjects were assessed for reproducibility by the
Bland and Altman test. The degree of reproducibility was expressed
as limits of agreements (mean difference1 2 SD) and was as follows:
nasal pH,20.136 and 0.116; exhaled pH,20.087 and10.085; nasal
FENO, 221.39 and 119.36; oral FENO, 21.158 and 1.122; exhaled
IL-5, 20.786 and 0.286; nasal IL-5, 20.698 and 0.688. Similar to
previous reports, we had an acceptable reproducibility.20-22
Data analysis
Data are expressed as mean 6 SD. The Kruskal-Wallis test and
Dunn procedure were used to compare different groups. The corre-
lations between variables were performed by using Spearman test
correlation. The significance was defined as P < .05.
RESULTS
Demographic, clinical, and atopic
characteristics of the subjects
Demographic, clinical, and atopic characteristics of the
subjects enrolled in the study are shown in Table I.
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Asthma
Characteristic Healthy AD AR Intermittent Moderate
Subject number 16 18 18 21 18
Male/female 8/16 11/18 11/18 12/21 12/18
Age (y) 10 6 2.4 10.1 6 2.3 9.9 6 2.9 10 .9 6 2.3 10.4 6 2.8
FEV1 (% predicted) 10 4 6 7.8 93 6 6.3 100.7 6 5 92.3 6 10.3 87.8 6 13.3
Total IgE (kU/mL) 87.1 6 17.1 480.6 6 297.4 489.7 6 333.5 771.4 6 333.8 639.5 6 231.7
Blood eosinophil
number (mm3)
45.7 6 17.5 644.6 6 297.4 585.6 6 305.3 495.1 6 209.9 548.6 6 165.6
Disease duration (y) None 5.3 6 2.1 3.6 6 2.0 4.1 6 1.2 5.6 6 2.4
Exacerbation number None None None 2 6 0.5 3.8 6 1.6
RAST to mite (kU/L) None 24.5 6 23.8 33.9 6 32.7 40.5 6 33.1 42.1 6 33.5
*Results were expressed as mean 6 SD.
Number of exacerbations during 12 months.
FIG 1. Levels of FENO of 16 healthy children and 18 with AD, 18 with AR, and 39 with asthma (21 intermittent
and 18 moderate). A, Levels of oral FENO. B, Levels of nasal FENO. Individual data are shown. Statistical anal-
ysis was by performed Kruskal-Wallis test and Dunn procedure. *P < .005.Exhaled FENO
The levels of oral FENO were significantly increased
in both (intermittent and moderate) groups with asthma
compared with HCs. No significant differences in oral
FENO were found among the AD, AR, and HC subjects.
Moreover, no significant differences were found between
the 2 groups of subjects with asthma (Fig 1, A). The levels
of nasal FENO were significantly increased in AR and in
both groups of children with intermittent and moderate
asthma with respect to healthy subjects. Significant in-
crease of the nasal FENO was also found in both groups
with asthma comparedwith AD andAR. Furthermore, sta-
tistically significant increase of nasal FENO was observed
in children with moderate asthma with respect to children
with intermittent asthma (Fig 1, B). The absolute values of
nasal and oral FENO are consistent with previous reports
using the same method.18,19,21
pH measurements in EBC
The pH levels of oral EBC were significantly lower in
children with AD and intermittent and moderate asthma
than in HCs. In addition, pH levels were significantly
lower in children with intermittent asthma than in childrenwithAD. Furthermore, the oral pH levels were significantly
lower in subjects with intermittent and moderate asthma
than in subjects with AR. Significantly lower values were
also found in children with intermittent than in children
with moderate asthma and in AD than in AR (Fig 2, A).
The pH levels in nasal EBCwere lower in children with
AD, AR, intermittent asthma, andmoderate asthma than in
healthy subjects (Fig 2, B).
IL-5 measurements in EBC
The IL-5 levels in oral EBCwere significantly higher in
subjects with intermittent asthma than in AD, AR, mod-
erate asthma, and HCs (Fig 3, A). The concentrations of
IL-5 in nasal EBC were significantly higher in children
with AR and intermittent and moderate asthma than in
HCs. Furthermore, significant differences were found
between patients with AD andmoderate asthma (Fig 3, B).
Correlation among FENO, pH, IL-5, and
biological and clinical outcomes
In AR, the levels of nasal FENO positively correlated
with the levels of IL-5 in nasal EBC (Fig 4, A) and with
the duration of the disease (Fig 4, B).
J ALLERGY CLIN IMMUNOL
VOLUME 118, NUMBER 5
Profita et al 1071
M
e
ch
a
n
is
m
s
o
f
a
st
h
m
a
a
n
d
a
ll
e
rg
ic
in
fl
a
m
m
a
ti
o
nFIG 2. Values of pH oral (A) and nasal (B) EBC of 16 healthy children, 18 with AD, 18 with AR, and 39
with asthma (21 intermittent and 18 moderate). Individual data are shown. Statistical analysis was
performed by Kruskal-Wallis test and Dunn procedure. *P < .005.
FIG 3. Levels of IL-5 in oral (A) and nasal (B) EBC of 16 healthy children, 18 with AD, 18 with AR, and 39
with asthma (21 intermittent and 18 moderate). Individual data are shown. Statistical analysis was
performed by Kruskal-Wallis test and Dunn procedure. *P < .005.
FIG 4. A, Correlation, in 18 children with AR, between nasal FENO and nasal IL-5 concentrations in EBC. B, Cor-
relation between nasal FENO and the duration of the disease. Individual data are shown. Statistical analysis
was performed by using Spearman correlation.In subjects with intermittent asthma, the presence of
exacerbations negatively correlated with the pH values in
both oral (Fig 5, A) and nasal EBC (Fig 5, B). We found a
positive correlation between IL-5 concentrations in oral
and nasal EBC and the levels of IgE in peripheral blood(Fig 6, A and B) in children with AD. Furthermore, in
children withmoderate asthma, the nasal levels of IL-5 pos-
itively correlated with the number of exacerbations (Fig 7).
We did not find any correlation between oral or nasal FENO
and IL-5 and the number of asthma exacerbations.
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peripheral blood in 18 children with AD. Individual data are shown. Solid circles, Children with mild AD.
Solid triangles, Children with moderate AD. Solid squares, Children with severe AD. Statistical analysis
was performed by using Spearman correlation.
FIG 5. Correlation between the pH values in oral (A) and nasal (B) EBC with the number of exacerbations in 21
subjects with intermittent asthma. Individual data are shown. Solid circles, Children with mild exacerbations.
Solid triangles, Children with moderate exacerbations. Statistical analysis was performed by using Spearman
correlation.FIG 7. Correlation between the levels of IL-5 in nasal EBC with
the number of exacerbations in 18 children with moderate
asthma. Statistical analysis was performed by using Spearman
correlation.DISCUSSION
Exhaled nitric oxide and EBC are noninvasive tech-
niques for the assessment of nasal and oral airway
inflammation in the atopic subjects with and without
asthma.7,23 The measurement of inflammatory parameters
in the nasal and in the bronchial compartments may
provide information about the general inflammatory status
and about the requirement of a local anti-inflammatory
therapy in the absence of clinical evidence.
In this study, we focused our attention on the role
played by the FENO and the levels of pH and IL-5 in the
EBC in the upper and lower airways of AD, AR, and
asthma. We observed increased levels of oral and nasal
FENO in children with asthma but not in children with
AD and AR. Lower pH values were observed in the oral
and nasal EBC of children with asthma, AD, and AR.
Moreover, the levels of oral IL-5 were increased in
children with intermittent asthma, whereas the levels of
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asthma.
Exhaled nitric oxide may be used as a sensitive,
noninvasive, and reproducible marker of asthma activity21
that correlates well with eosinophilic airway inflamma-
tion. In addition, FENO levels seem to be associated with
a mechanism linking atopy and airway responsiveness
in diseases such as AD and AR without symptoms of
bronchial obstruction.24 Recent data showed a relation-
ship among FENO, respiratory symptoms, lung function,
bronchial responsiveness, blood eosinophilia, and high
serum levels of total IgE.25 According to these concepts,
our observations of the higher levels of oral and nasal
FENO in patients with asthma are probably a result of the
elevated grade of atopy (high levels of serum IgE).25
Interestingly, the observed absence of a significant differ-
ence in oral FENO between children with intermittent and
moderate asthma demonstrates that despite the use of
inhaled corticosteroids (ICSs), increased levels of markers
of oxidative stress and elevated levels of eosinophils
persist in some of these patients. These findings suggest
the possibility to use this methodology in children to mon-
itor the efficacy of the therapy on this specific parameter.26
Moreover, the trend to the increase of oral FENO inAD and
AR with respect to controls supports the hypothesis that
this marker might predict and monitor the increased risk
to develop bronchial inflammation in atopic children4
even in the absence of symptoms of asthma.23
The concept of an association between the FENO and
the airway inflammation in children is supported by the
presence, in AR, of a significant increase of nasal FENO
and of a positive correlation between the nasal FENO
and the levels of nasal IL-5 in EBC. Accordingly, we
also found a positive correlation between the nasal FENO
and the duration of rhinitis. These observations further
support the concept of the role of the nasal FENO detection
as reliable noninvasive marker useful to monitor the nasal
inflammation5 to predict the risk for developing asthma.27
The apparent discordance between oral and nasal FENO
and EBC pH in asthma and AD is probably a result of
the different causes of modification of the 2 parameters.
FENO is principally a product of activated macrophages,
eosinophils, and airway epithelial cells,28 and the varia-
tion of pH is caused by a wide variety of inflammatory
pathways.29 Finally, the increased levels of nasal FENO
observed in patients with moderate asthma are related to
a persistent inflammation in the upper airways, suggesting
the need to use a nasal anti-inflammatory therapy in these
subjects.3 We did not find any correlations between oral
or nasal FENO and the number of asthma exacerbations,
possibly because there are some patients with values
overlapping with control subjects. Further studies are nec-
essary to verify the possible use of the measurement of
nasal and oral FENO to predict the risk of exacerbations.
30
The measurement of the pH values is considered a
readily measurable marker of airway disease.10 Accord-
ingly, we showed lower values of pH in patients with in-
termittent and moderate asthma than in the other groups
of patients and in controls. The relative low increase ofthe pH values in the oral EBC from patients with moderate
asthma with respect to patients with intermittent asthma
are probably related to the use of oral ICSs in the conven-
tional treatment of these patients, with a consequent partial
reduction of the bronchial inflammatory status.10 The ab-
sence of a statistical difference in the nasal EBC pH values
between these 2 groups of subjects, together with the pres-
ence of a difference between AD and controls, further sup-
ports this hypothesis. It is accepted that the lower values of
pH are associated with the presence of an eosinophilic in-
flammation of the airways in asthma.9 This concept was
expanded by the observed relationship of oral and nasal
pH values with the presence of exacerbations. The
findings that oral and nasal pH values are lower in AD
and AR confirm that in atopics, the presence of the airway
inflammation may be considered a marker of progression
toward the development of bronchial asthma.2-5 More-
over, this noninvasive technique can be used to monitor
the ongoing nasal and bronchial inflammatory status
in children with atopic diseases including rhinitis and
asthma. These observations support the concept that sub-
jects with asthma should be well evaluated and treated for
rhinitis. This combined nasal and bronchial therapeutic
strategy proposed in adults2,3 should be ideally used for
the treatment of upper and lower airway inflammation in
children.
IL-5 actively contributes to the local infiltration and
activation of eosinophils in asthma and in other allergic
diseases.31 In this study, we observed the relevant contri-
bution of IL-5 in lower and upper airway inflammation as-
sociated with asthma. The relatively low concentrations of
IL-5 in the oral EBC from patients with moderate asthma
with respect to patients with intermittent asthma is proba-
bly related to the local treatment with ICSs in patients with
moderate asthma. Accordingly, the levels of IL-5 in the
nasal EBC of the same patients were further increased
with respect to the other groups of subjects. The IL-5 con-
centrations in both the upper and the lower airways had
been demonstrated to be related to the degree of eosino-
philic inflammation in asthma.9 Moreover, previous stud-
ies reported high levels of nasal IL-5 in atopic children
with asthma and rhinitis,32 confirming the relevant contri-
bution of upper airway inflammation in asthma.3 In our
children with moderate asthma, the positive correlation
between the nasal IL-5 levels and the number of exacerba-
tions of patients with moderate asthma suggests that the
persistent uncontrolled inflammation of the upper airways
may represent a potential trigger for exacerbations in oral
ICS-treated children with asthma. Furthermore, the detec-
tion of high concentrations of IL-5 in nasal EBC from chil-
dren with moderate asthma might be considered a marker
of the persistence of airway inflammation, which might
lead to the development of exacerbations in this specific
group of patients. We did not find any correlations be-
tween oral or nasal FENO or IL-5 and the number of asthma
exacerbations. The trend toward increased levels of oral
and nasal IL-5 in AD with respect to controls suggests
that IL-5 plays a role in eosinophilic inflammation in
AD, involving both the upper and lower airways. This
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and nasal IL-5 with the total levels of IgE in peripheral
blood of children with AD in association with the degree
of the disease. Subjects with allergy were characterized
by increased levels of IL-4 and IL-5. The elevated levels
of IL-4may generate the elevated IgE levels found in these
subjects.33
Taken together, these observations underline the con-
cept that high levels of IL-5 associated with high levels of
IgE and a higher degree of eczema in AD may be predic-
tive for a clear risk of inflammation of the upper and lower
airways marching to the development of rhinitis and
asthma.34,35
In conclusion, this study shows a relevant contribution
of FENO and of somemediators present in EBC as markers
of upper and lower airway inflammation in children with
atopic diseases. The presence of low values of these
markers in a subgroup of patients overlapping with the
normal subjects suggests the need for further studies to
identify a cutoff to define the normal and the pathologic
ranges of these parameters. To our knowledge, this is
the first report suggesting the potential use of these non-
invasive techniques for the identification of children
with atopic disorders different from asthma to develop
bronchial asthma and to predict, in children with asthma,
the development of an exacerbation.
The study benefited from the experience gained in the context of
the European Union Program GA2LEN, Global Allergy and Asthma
European Network.
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